1. Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial. (January 2019) Authors: Kim, D.; Huber, R.; Ahn, M.; Langer, C.; Tiseo, M.; West, H.; Groen, H.; Reckamp, K.; Hochmair, M.; Leighl, N.; Hansen, K.H.; Gettinger, S.; Paz-Ares Rodriguez, L.; Kim, E.; Smit, E.; Kim, S.; Reichmann, W.; Kerstein, D.; Camidge, D.R. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial. (January 2020) Authors: Califano, R.; Camidge, D.; Kim, H.-R.; Ahn, M.-J.; Yang, J.; Han, J.-Y.; Hochmair, M.; Lee, K.H.; Delmonte, A.; Campelo, M.R. Garcia; Kim, D.-W.; Griesinger, F.; Felip, E.; Spira, A.; Gettinger, S.; Tiseo, M.; Ni, Q.; Zhang, P.; Popat, S. Journal: Lung cancer Issue: Volume 139(2020)Supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Global named patient use (NPU) program of afatinib in heavily pretreated advanced NSCLC patients who progressed following prior therapies, including erlotinib or gefitinib. (February 2017) Authors: Hochmair, M.; Cappuzzo, F.; Tsai, C.M.; Schuler, M.; Lam, K.C.; Stehle, G.; Cseh, A.; Lorence, R.M.; Linden, S.; Carrière, P.; Soo, R. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study. (January 2019) Authors: Hochmair, M.; Cufer, T.; Morabito, A.; Hao, D.; Ta Yang, C.; Soo, R.; Yang, J.; Gucalp, R.; Halmos, B.; Wang, L.; Golembesky, A.; Märten, A.; O'Byrne, K. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study. (January 2019) Authors: Hochmair, M.; Cufer, T.; Morabito, A.; Hao, D.; Yang, C.; Soo, R.; Yang, J.C.; Rasim Gucalp, R.; Halmos, B.; Wang, L.; Golembesky, A.; Märten, A.; O'Byrne, K. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗